- The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization
-
Tan D, Fujiwara N, Fujiwara K, Beale P, Kim JW, Ng J, Kim SI, Evans A, Kim BG, on behalf of The Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
- KMID: 2552525
- J Gynecol Oncol.
- 2023 Mar;34(2):e33.
- doi: 10.3802/jgo.2023.34.e33
-
- CITED
-
- Close
- SHARE
-
- Close
- Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3
-
Lee JY, Lee YY, Park JY, Shim SH, Kim SI, Kong TW, Lim CK, Cho HW, Suh DH
- KMID: 2552526
- J Gynecol Oncol.
- 2023 Mar;34(2):e51.
- doi: 10.3802/jgo.2023.34.e51
In the 2022 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review... -
- CITED
-
- Close
- SHARE
-
- Close
- Intraoperative frozen pathology exam of Common iliac lymph nodes and Para-Aortic lymphadenectomy on the prognosis and quality of life for patients with IB2-IIA2 Cervical Cancer: trial protocol for a randomized controlled trial (C-PACC trial)
-
Qu X, Qiu J, Jiang L, Qi X, Zhang G, Feng W, Wang Y, Teng Y, Wang X, Guo X, Hua K
- KMID: 2552522
- J Gynecol Oncol.
- 2023 Mar;34(2):e13.
- doi: 10.3802/jgo.2023.34.e13
Background The impact of para-aortic lymphadenectomy (PALD) on prognosis and quality of life (QoL) for IB2-IIA2 cervical cancer patients remain controversial. And whether intraoperative frozen pathology exam on common iliac lymph... -
- CITED
-
- Close
- SHARE
-
- Close
- Number of FoxP3+ regulatory T-cells are associated with recurrence in vulvar squamous cell carcinoma
-
Arık D, Benli T, Telli E
- KMID: 2552517
- J Gynecol Oncol.
- 2023 Mar;34(2):e16.
- doi: 10.3802/jgo.2023.34.e16
Objective Surgical management is essential in early-stage vulvar squamous cell carcinoma (SCC), but these surgical procedures often cause significant morbidity. Immunotherapy may be a new treatment option in these patients. FoxP3+... -
- CITED
-
- Close
- SHARE
-
- Close
- Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study
-
Chu R, Liu P, Chen J, Cheng X, Li K, Che Y, Wang J, Li L, Zhang X, Yao S, Song L, Zhao Y, Huang C, Xue Y, Pan X, Li J, Chen Z, Jiang J, Kong B, Song K
- KMID: 2552512
- J Gynecol Oncol.
- 2023 Mar;34(2):e12.
- doi: 10.3802/jgo.2023.34.e12
Objective To evaluate the impact of bleomycin/etoposide/cisplatin (BEP) and paclitaxel/carboplatin (PC) chemotherapy regimens on the fertility and prognostic outcomes in malignant ovarian germ cell tumor (MOGCT) patients who underwent fertility-sparing surgery... -
- CITED
-
- Close
- SHARE
-
- Close
- Low-grade endometrial stromal sarcoma with intravenous thrombus extension: a multidisciplinary surgical challenge
-
Guijarro-Campillo AR, Vidal BS, Lago V, Padilla-Iserte P, Chinchilla JAH, Martín-González I, Pozo SDd
- KMID: 2552524
- J Gynecol Oncol.
- 2023 Mar;34(2):e21.
- doi: 10.3802/jgo.2023.34.e21
Low-grade endometrial stromal sarcoma (LG-ESS) usually exhibits indolent behavior, often misdiagnosed and is associated with a favorable prognosis [1]. Despite the indolent nature of LG-ESS, recurrence is common, the risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Incidence and treatment outcomes of uterine cervical cancer in Korea 1999–2018 from the national cancer registry
-
Suh DH, Ha HI, Lee YJ, Lim J, Won YJ, Lim MC
- KMID: 2552521
- J Gynecol Oncol.
- 2023 Mar;34(2):e39.
- doi: 10.3802/jgo.2023.34.e39
Objective To describe the incidence and survival outcomes of uterine cervical cancer during 1999–2018. Methods Patients who were diagnosed with cervical cancer during 1999–2018 were identified in the Korea Central Cancer Registry. Age-standardized... -
- CITED
-
- Close
- SHARE
-
- Close
- Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT)
-
Li Y, Zhu C, Xie H, Chen Y, Lv W, Xie X, Wang X
- KMID: 2552523
- J Gynecol Oncol.
- 2023 Mar;34(2):e37.
- doi: 10.3802/jgo.2023.34.e37
Background The use of molecular categorisation is shifting paradigm towards the use of molecular information to refine risk stratification in endometrial cancer (EC). To date, evidence to support molecular-guided therapies is... -
- CITED
-
- Close
- SHARE
-
- Close
- Role of diagnostic laparoscopy in deciding primary treatment in advanced-stage ovarian cancer
-
Lee YJ, Chung YS, Lee JY, Nam EJ, Kim SW, Kim YT, Kim S
- KMID: 2552514
- J Gynecol Oncol.
- 2023 Mar;34(2):e17.
- doi: 10.3802/jgo.2023.34.e17
Objective We evaluated the usefulness of preoperative diagnostic laparoscopy for treatment planning in patients with advanced-stage ovarian cancer. Methods We retrospectively analyzed 614 patients diagnosed with advanced-stage ovarian cancer between January 2010 and... -
- CITED
-
- Close
- SHARE
-
- Close
- A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma
-
Micha JP, Rettenmaier MA, Bohart RD, Goldstein BH
- KMID: 2552513
- J Gynecol Oncol.
- 2023 Mar;34(2):e15.
- doi: 10.3802/jgo.2023.34.e15
Objective The purpose of this study was to assess the efficacy and tolerability of a paclitaxel, carboplatin and metformin regimen in the first-line treatment of advanced-stage ovarian, fallopian tube, and primary... -
- CITED
-
- Close
- SHARE
-
- Close
- Validation of HPV triage in cytology-based cervical cancer screening for ASC-US cases using Japanese data
-
Aoki ES, Saika K, Kiguchi K, Morisada T, Aoki D
- KMID: 2552515
- J Gynecol Oncol.
- 2023 Mar;34(2):e14.
- doi: 10.3802/jgo.2023.34.e14
Objective In Japan, cervical cancer screening consists of a cytology examination performed once every 2 years. We verified whether the risk of cervical intraepithelial neoplasia (CIN) 3 disease or higher (CIN3+)... -
- CITED
-
- Close
- SHARE
-
- Close
- CircSMAD2 accelerates endometrial cancer cell proliferation and metastasis by regulating the miR-1277-5p/MFGE8 axis
-
Wu Y, Wang F, Shi J, Guo X, Li F
- KMID: 2552519
- J Gynecol Oncol.
- 2023 Mar;34(2):e19.
- doi: 10.3802/jgo.2023.34.e19
Objective Endometrial cancer (EC) is a common gynecological malignant tumor. CircRNAs play crucial roles in cancer progression and metastasis. However, the biological functions of circRNAs in EC remain largely unknown. Methods CircSMAD2, miR-1277-5p,... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk factors for and delayed recognition of genitourinary fistula following radical hysterectomy for cervical cancer: a population-based analysis
-
Liang C, Liu P, Kang S, Li W, Chen B, Ji M, Chen C
- KMID: 2552516
- J Gynecol Oncol.
- 2023 Mar;34(2):e20.
- doi: 10.3802/jgo.2023.34.e20
Objective This study aimed to identify the risk factors for genitourinary fistulas and delayed fistula recognition after radical hysterectomy for cervical cancer. Methods This study was a retrospective analysis of data collected in... -
- CITED
-
- Close
- SHARE
-
- Close
- Levonorgestrel-releasing intrauterine system-based therapies for early-stage endometrial cancer: a systematic review and meta-analysis
-
Wei H, Pan N, Zhang W, Xiong G, Guo W, Dong Z, Ma C
- KMID: 2552520
- J Gynecol Oncol.
- 2023 Mar;34(2):e36.
- doi: 10.3802/jgo.2023.34.e36
Objective To conduct a systematic review and meta-analysis of studies evaluating the oncological and fertility outcomes of early-stage endometrial cancer (EC) treated with the levonorgestrel-releasing intrauterine system (LIUS)-based regimens. Methods The Meta-analyses Of... -
- CITED
-
- Close
- SHARE
-
- Close
- Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer
-
Hong JH, Cho HW, Ouh YT, Lee JK, Chun Y
- KMID: 2552518
- J Gynecol Oncol.
- 2023 Mar;34(2):e18.
- doi: 10.3802/jgo.2023.34.e18
Objective Immune checkpoint inhibitors have been widely used in the treatment of endometrial cancer (EC) with microsatellite instability-hypermutated (MSI-H). However, there is an unmet need for microsatellite stable (MSS) EC because... -
- CITED
-
- Close
- SHARE
-
- Close
